Simplify Asset Management Inc. Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Simplify Asset Management Inc. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 34.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,258 shares of the biopharmaceutical company's stock after selling 3,333 shares during the quarter. Regeneron Pharmaceuticals comprises 0.2% of Simplify Asset Management Inc.'s investment portfolio, making the stock its 27th biggest holding. Simplify Asset Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $4,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $34,468,000. Umpqua Bank raised its position in shares of Regeneron Pharmaceuticals by 7.6% during the fourth quarter. Umpqua Bank now owns 1,534 shares of the biopharmaceutical company's stock worth $1,060,000 after purchasing an additional 108 shares during the period. Forefront Wealth Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $2,206,000. Mizuho Securities USA LLC grew its position in Regeneron Pharmaceuticals by 45.0% in the 4th quarter. Mizuho Securities USA LLC now owns 9,977 shares of the biopharmaceutical company's stock valued at $7,107,000 after purchasing an additional 3,096 shares during the period. Finally, Quantbot Technologies LP increased its stake in Regeneron Pharmaceuticals by 266.7% during the 4th quarter. Quantbot Technologies LP now owns 528 shares of the biopharmaceutical company's stock valued at $376,000 after purchasing an additional 384 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $4.31 on Thursday, hitting $635.83. 811,470 shares of the stock traded hands, compared to its average volume of 642,150. The firm has a market capitalization of $69.51 billion, a price-to-earnings ratio of 16.61, a PEG ratio of 2.34 and a beta of 0.27. The business's fifty day moving average is $684.76 and its two-hundred day moving average is $803.87. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 12 month low of $629.02 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.86 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Analyst Ratings Changes

A number of research analysts have weighed in on REGN shares. Sanford C. Bernstein dropped their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a report on Tuesday, February 4th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.